Three additional PDXs were established from a 65-year-old European American patient with a germline BRCA2 mutation (Y2215fs) who underwent resection for a noninvasive urothelial carcinoma of the bladder a year before having a prostate biopsy that was positive for Gleason 9 PC with perineural invasion. Here, BRCA2 is linked to bladder transitional cell carcinoma.